Werewolf Therapeutics (NASDAQ:HOWL) Stock Rating Reaffirmed by JMP Securities

JMP Securities reaffirmed their market outperform rating on shares of Werewolf Therapeutics (NASDAQ:HOWL) in a research note published on Monday, Benzinga reports. JMP Securities currently has a $12.00 price objective on the stock.

Separately, HC Wainwright reissued a buy rating and set a $15.00 price target on shares of Werewolf Therapeutics in a research report on Monday.

Werewolf Therapeutics Stock Performance

HOWL opened at $5.98 on Monday. Werewolf Therapeutics has a one year low of $1.57 and a one year high of $8.19. The company has a quick ratio of 7.14, a current ratio of 7.14 and a debt-to-equity ratio of 0.29. The stock’s 50 day moving average price is $6.21 and its 200-day moving average price is $4.67.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings data on Thursday, March 7th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.10. The company had revenue of $1.50 million during the quarter, compared to analysts’ expectations of $2.75 million. Werewolf Therapeutics had a negative net margin of 256.33% and a negative return on equity of 36.43%. On average, sell-side analysts forecast that Werewolf Therapeutics will post -1.38 earnings per share for the current year.

Hedge Funds Weigh In On Werewolf Therapeutics

Several institutional investors have recently bought and sold shares of HOWL. PFM Health Sciences LP lifted its holdings in Werewolf Therapeutics by 35.6% during the fourth quarter. PFM Health Sciences LP now owns 3,468,177 shares of the company’s stock worth $13,387,000 after buying an additional 909,895 shares during the period. Denali Advisors LLC bought a new position in shares of Werewolf Therapeutics in the 1st quarter worth $172,000. Lighthouse Investment Partners LLC purchased a new stake in shares of Werewolf Therapeutics during the 4th quarter worth $87,000. Certuity LLC purchased a new stake in shares of Werewolf Therapeutics during the 4th quarter worth $39,000. Finally, Financial Perspectives Inc boosted its position in Werewolf Therapeutics by 80.0% during the fourth quarter. Financial Perspectives Inc now owns 6,750 shares of the company’s stock valued at $26,000 after purchasing an additional 3,000 shares in the last quarter. 64.84% of the stock is owned by hedge funds and other institutional investors.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.